Overview

Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This trial will assess the safety and efficacy of ACZ885 in patients with active recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS).
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals